X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (68) 68
humans (63) 63
infectious diseases (44) 44
male (39) 39
female (36) 36
hepatitis c (33) 33
middle aged (32) 32
adult (31) 31
hepatitis (30) 30
hepatitis c virus (30) 30
hiv (30) 30
hepatitis c, chronic - drug therapy (28) 28
article (27) 27
antiviral agents - therapeutic use (25) 25
immunology (23) 23
genotype (20) 20
human immunodeficiency virus--hiv (20) 20
microbiology (20) 20
treatment outcome (18) 18
virus diseases (18) 18
hcv (17) 17
care and treatment (16) 16
hiv infections - complications (16) 16
hiv infections - drug therapy (16) 16
infection (16) 16
abridged index medicus (15) 15
gastroenterology & hepatology (15) 15
hepatitis c, chronic - virology (15) 15
antiviral agents - adverse effects (14) 14
drug therapy (14) 14
hepacivirus - genetics (14) 14
hepatitis c, chronic - complications (14) 14
ribavirin (14) 14
therapy (14) 14
il28b (13) 13
ribavirin - therapeutic use (13) 13
sofosbuvir (13) 13
genotype & phenotype (12) 12
genotype 1 infection (12) 12
hepatitis c - drug therapy (12) 12
human immunodeficiency virus (12) 12
human-immunodeficiency-virus (12) 12
united-states (12) 12
virology (12) 12
viruses (12) 12
aged (11) 11
analysis (11) 11
health aspects (11) 11
hiv infection (11) 11
interleukins - genetics (11) 11
research (11) 11
risk factors (11) 11
antiviral agents (10) 10
antiviral agents - administration & dosage (10) 10
drug therapy, combination (10) 10
hiv infections - virology (10) 10
interferon (10) 10
association (9) 9
cirrhosis (9) 9
digestive system diseases (9) 9
gastroenterology and hepatology (9) 9
polyethylene glycols - therapeutic use (9) 9
chronic hepatitis-c (8) 8
dosage and administration (8) 8
infections (8) 8
interferon-alpha - therapeutic use (8) 8
mortality (8) 8
patients (8) 8
plus ribavirin (8) 8
polymorphism (8) 8
retrospective studies (8) 8
ribavirin - administration & dosage (8) 8
ribavirin - adverse effects (8) 8
sustained virological response (8) 8
viral load (8) 8
aids/hiv (7) 7
antiretroviral drugs (7) 7
antiretroviral therapy (7) 7
cohort studies (7) 7
coinfection (7) 7
comorbidity (7) 7
hepatitis-c virus (7) 7
hiv infections - epidemiology (7) 7
interferon alpha-2 (7) 7
ledipasvir (7) 7
liver cirrhosis (7) 7
liver fibrosis (7) 7
medicine & public health (7) 7
medicine, general & internal (7) 7
polymorphism, single nucleotide (7) 7
transient elastography (7) 7
veterans (7) 7
alpha-2a plus ribavirin (6) 6
coinfection - drug therapy (6) 6
epidemiology (6) 6
genetic aspects (6) 6
genotypes (6) 6
hepacivirus - classification (6) 6
hepatitis c, chronic - genetics (6) 6
hepatology (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Topics in antiviral medicine, 01/2019, Volume 26, Issue 4, pp. 104 - 108
Journal Article
Topics in antiviral medicine, ISSN 2161-5861, 02/2017, Volume 25, Issue 1, pp. 3 - 6
There is evidence that hepatitis C virus (HCV) infection, like HIV infection, may be associated with chronic inflammation, immune activation, and immune... 
Inflammation - pathology | Hepatitis C, Chronic - pathology | Cellular Senescence | Humans | Liver Cirrhosis - pathology | Hepacivirus - pathogenicity | Hepatitis C, Chronic - complications | extrahepatic disease | HIV | inflammation | immune activation | HCV | fibrosis | immune senescence
Journal Article
JAMA - Journal of the American Medical Association, ISSN 0098-7484, 2019, Volume 322, Issue 4, pp. 355 - 356
This JAMA Insights Clinical Update reviews current standards of management of HCV infection, including use of antibody and RNA tests to identify infected... 
MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | Antiviral agents | Dosage and administration | Hepatitis C | Drug therapy | Risk factors | Hepatitis | Disease management | Hepatitis C virus | Antiviral drugs
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 06/2017, Volume 64, Issue 12, pp. 1721 - 1723
Journal Article
PLoS Pathogens, ISSN 1553-7366, 06/2015, Volume 11, Issue 6, p. e1004854
Journal Article
Annual Review of Medicine, ISSN 0066-4219, 01/2017, Volume 68, p. 345
  The current standard of care for the treatment of hepatitis C virus (HCV) consists of interferon-free direct-acting antiviral (DAA) regimens, including... 
Hepatitis | Transplants & implants | Antiviral drugs | Drug dosages
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 8, pp. 705 - 713
Among patients coinfected with HIV-1 and HCV genotype 1 or 4 who were receiving effective antiretroviral therapy, treatment with 12 weeks of ledipasvir and... 
MEDICINE, GENERAL & INTERNAL | HEPATOCELLULAR-CARCINOMA | INTERFERON | THERAPY | HEPATITIS-C VIRUS | CIRRHOSIS | ALPHA-2A PLUS RIBAVIRIN | VETERANS | GENOTYPE 1 INFECTION | COHORT | LIVER-DISEASE | HIV-1 | Humans | Middle Aged | Drug Resistance, Viral | Fluorenes - therapeutic use | Hepacivirus - genetics | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Viral Load | Female | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Fluorenes - pharmacokinetics | Hepacivirus - isolation & purification | Anti-Retroviral Agents - therapeutic use | Antiviral Agents - therapeutic use | Benzimidazoles - pharmacokinetics | Genotype | Hepatitis C, Chronic - drug therapy | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | HIV Infections - complications | HIV Infections - drug therapy | Uridine Monophosphate - pharmacokinetics | Sofosbuvir | Care and treatment | Research | Hepatitis C virus | HIV infection | Emtricitabine | Headache | Antiretroviral drugs | Inhibitor drugs | Diarrhea | Fatigue | Patients | Efavirenz | Studies | Tenofovir | Cirrhosis | Genotype & phenotype | Hepatitis | Human immunodeficiency virus--HIV | Hepatitis C | Drug therapy | Genotypes
Journal Article
Drugs, ISSN 0012-6667, 2/2017, Volume 77, Issue 2, pp. 131 - 144
Journal Article
Journal Article
Lancet (London, England), ISSN 0140-6736, 3/2015, Volume 385, Issue 9973, pp. 1052 - 1054
Journal Article
PLoS Pathogens, ISSN 1553-7366, 06/2015, Volume 11, Issue 6
  Specifically, patients with HIV/HCV dual infection, patients with compensated and decompensated cirrhosis, and patients who have had liver transplantation... 
Liver diseases | Transplants & implants | Mortality | Infections | Genomes | Genetic diversity | Patients | Proteins | Hepatitis | Genotype & phenotype | Liver cancer | Infectious diseases | Human immunodeficiency virus--HIV | Response rates | Liver cirrhosis
Journal Article
Digestive Diseases and Sciences, ISSN 0163-2116, 12/2019, Volume 64, Issue 12, pp. 3394 - 3401
Liver disease is a leading cause of non-AIDS-related death in the HIV population since the introduction of highly active antiretroviral treatment (HAART).... 
Biochemistry, general | NAFLD | Transient elastography | Medicine & Public Health | HIV | Hepatology | Gastroenterology | Oncology | NASH | Transplant Surgery
Journal Article
Gastroenterology, ISSN 0016-5085, 2012, Volume 142, Issue 6, pp. 1324 - 1334.e3
With the development of effective therapies against human immunodeficiency virus (HIV), hepatitis C virus (HCV) infection has become a major cause of morbidity... 
Gastroenterology and Hepatology | Drug Interaction | HCV | Treatment | HIV | Liver Disease | ANTIRETROVIRAL THERAPY | RANDOMIZED CONTROLLED-TRIAL | HUMAN-IMMUNODEFICIENCY-VIRUS | NATURAL-HISTORY | LIVER-DISEASE | SEXUAL TRANSMISSION | HEPATITIS-C VIRUS | ALPHA-2A PLUS RIBAVIRIN | GENOTYPE 1 INFECTION | PEGYLATED INTERFERON-ALPHA-2B | GASTROENTEROLOGY & HEPATOLOGY | Recombinant Proteins - therapeutic use | Coinfection | Antiviral Agents - pharmacokinetics | HIV Infections - epidemiology | Humans | Hepatitis C, Chronic - etiology | Male | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Tenofovir | Deoxycytidine - therapeutic use | Drug Interactions | Homosexuality, Male | Adenine - therapeutic use | Lamivudine - therapeutic use | Anti-HIV Agents - therapeutic use | Dideoxynucleosides - therapeutic use | Hepatitis C, Chronic - epidemiology | Drug Therapy, Combination | Raltegravir Potassium | Substance Abuse, Intravenous - complications | Emtricitabine | Liver Diseases - virology | Antiviral Agents - pharmacology | Adenine - analogs & derivatives | Drug Administration Schedule | Organophosphonates - therapeutic use | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Liver Diseases - prevention & control | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Pyrrolidinones - therapeutic use | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Disease Progression | Proline - therapeutic use | HIV Infections - etiology | Liver Cirrhosis - virology | Antiviral Agents - adverse effects | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Antiviral agents | Medical colleges | Care and treatment | Liver diseases | Comorbidity | Drug interactions | Mortality | Development and progression | Biological response modifiers | HIV (Viruses) | Hepatitis | Protease inhibitors | Proteases | Hepatitis C virus | Hepatitis C | Health aspects | HIV infection | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Annual Review of Medicine, ISSN 0066-4219, 1/2017, Volume 68, Issue 1, pp. 345 - 358
The current standard of care for the treatment of hepatitis C virus (HCV) consists of interferon-free direct-acting antiviral (DAA) regimens, including... 
kidney transplant | decompensated cirrhosis, liver transplant | end-stage liver disease | HCV, direct-acting antiviral, HIV HCV coinfection | HCV, direct-acting antiviral, HIV/HCV coinfection | Kidney transplant | Decompensated cirrhosis, liver transplant | End-stage liver disease | MEDICINE, RESEARCH & EXPERIMENTAL | OPEN-LABEL | NATURAL-HISTORY | HCV INFECTION | direct-acting antiviral | decompensated cirrhosis | PEGINTERFERON ALPHA-2B | GENOTYPE 1 INFECTION | HCV | HIV/HCV coinfection | CHRONIC KIDNEY-DISEASE | liver transplant | ADVANCED LIVER-DISEASE | DACLATASVIR PLUS SOFOSBUVIR | STAGE RENAL-DISEASE | Recurrence | Liver Transplantation | Kidney Failure, Chronic - surgery | Hepatitis C - drug therapy | Administration, Oral | Antiviral Agents - therapeutic use | Coinfection - drug therapy | Humans | Drug Resistance, Viral | Hepacivirus - genetics | Genotype | Secondary Prevention - methods | Antiviral Agents - administration & dosage | Drug Therapy, Combination - methods | Liver Cirrhosis - virology | Kidney Failure, Chronic - virology | Treatment Failure | HIV Infections - drug therapy | Hepatitis C - complications | Hepatitis C - physiopathology | Liver Cirrhosis - surgery | Antiviral agents | Complications and side effects | Usage | Dosage and administration | Drug therapy, Combination | Research | Hepatitis C | Drug therapy
Journal Article